Overview:
On October 21, 2020, China’s Center for Drug Evaluation (CDE) released “Technical Requirements for Quality and Efficacy Consistency Evaluation of Generic Chemical Injections.” In order to guide the research and development of chemical drug injections in China.
The guidance expands on the following topics:
- Reference Listed Drug
Technical Requirements for Formulation
- Technical Requirements for Quality Control of APIs, Excipients and Packaging Materials
- Technical Requirements for Quality Study and Control
- Technical Requirements for Stability Studies
Basic Considerations for Consistency Evaluation of Special Injections
Basic Considerations for Strength-modified (Including different drug substance concentrations) Injections
Drafting of Package Insert
- Specification of Drug Products
Injections Requiring No Consistency Evaluation
Reference Listed Drug (RDL)
The applicant must select the reference listed drug (RLD) using Procedures for Selection and Determination of Generic Chemical Reference Listed Drugs issued by the National Medical Products Administration (NMPA) and carry out the consistency evaluation research with reference to the technical requirements specified in this document as well as relevant technical guidelines in China and abroad.
Technical Requirements for Formulation
The type and amount of excipients contained in the injection shall generally be the same as the reference listed drug (RLD). The amount in the generic drug is 95%-105% the amount of corresponding excipients contained in the RLD.
If Special solvent(s) are contained, they shall be consistent with that (those) of the RLD in terms of formulation.
Injections That do not need Consistency Evaluation
Injections such as sodium chloride injection, glucose injection, glucose and sodium chloride injection, water for injection and some radioactive drugs (such as technetium [99mTc]) are not required to undergo consistency evaluation, but are still subject to quality improvement research.
About Global Regulatory Partners
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices and pharmaceutical companies globally. GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and Argentina. GRP helps many life science companies register their products in different countries in compliance with local regulations. To learn more, please contact us at info@globalregulatorypartners.com
Navigate the Global Regulatory Landscape
Follow GRP on Social Media
Subscribe to our Blogs & Newsletter
https://globalregulatorypartners.com/countries/asia/china-national-national-medical-products-administration-nmpa/